Africa: Malaria Vaccine Becomes First to Achieve WHO-specified 75% Efficacy Goal
[Oxford University] Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.
Source: AllAfrica News: Malaria - Category: Infectious Diseases Source Type: news
More News: African Health | Infectious Diseases | Malaria | Malaria Vaccine | Oxford University | Vaccines